BS_V72GX2AZ
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 32.8515111695138
- age_years
- 14.792
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.520
- INTERFERON_GAMMA_RESPONSE+0.516
- ALLOGRAFT_REJECTION+0.499
- IL6_JAK_STAT3_SIGNALING+0.481
- INTERFERON_ALPHA_RESPONSE+0.481
- COMPLEMENT+0.387
- INFLAMMATORY_RESPONSE+0.376
- KRAS_SIGNALING_UP+0.355
- TGF_BETA_SIGNALING+0.348
- IL2_STAT5_SIGNALING+0.334
Top 10 suppressed
- MYC_TARGETS_V2-0.420
- DNA_REPAIR-0.309
- UV_RESPONSE_UP-0.207
- KRAS_SIGNALING_DN-0.145
- WNT_BETA_CATENIN_SIGNALING-0.142
- E2F_TARGETS-0.114
- APICAL_JUNCTION-0.111
- CHOLESTEROL_HOMEOSTASIS-0.072
- PANCREAS_BETA_CELLS-0.068
- SPERMATOGENESIS-0.067
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_0SCXXM6N | low-grade glioma | — | 0.919 |
| 2 | BS_HQ5BJ6MW | pilocytic astrocytoma | — | 0.895 |
| 3 | BS_014EVM2D | low-grade glioma | — | 0.889 |
| 4 | BS_QRNSKFMS | pilocytic astrocytoma | — | 0.889 |
| 5 | BS_S4V9E1XJ | pilocytic astrocytoma | — | 0.885 |
| 6 | BS_VP5Y45Z7 | pilocytic astrocytoma | — | 0.885 |
| 7 | BS_Q79NP5YY | pilocytic astrocytoma | — | 0.880 |
| 8 | SJEPD031078_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.865 |
| 9 | BS_F8N6CFQE | low-grade glioma | — | 0.863 |
| 10 | 53933_S131 | — | cohortA1 | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.520 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.516 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.499 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.481 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.481 | Inavolisib | — uncovered |
| COMPLEMENT | 0.387 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.376 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.355 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.348 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.334 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.272 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.267 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.247 | Inavolisib | — uncovered |
| COAGULATION | 0.232 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.219 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.207 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.198 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |